gastric cancer

Research Reports

Patterns and Predictors of Treatment Choice in a Real-World Cohort of Patients with Metastatic Gastric Cancer in the United States

09/22/2021

Thomas A Abrams, MD

Gary Meyer, PhD

Lisa M Hess, PhD

Sui Zhang, MS, MPP

Astra M Liepa, PharmD

Yajun Zhu, MS

Jeffrey A Meyerhardt, MD, MPH

Deborah Schrag, MD, MPH

Peter C Enzinger, MD

Charles S Fuchs

Thomas A. Abrams, MD, and colleagues examine patterns of systemic therapy administration in metastatic gastric cancer and the predictors associated with specific treatment choices.

Thomas A. Abrams, MD, and...

09/22/2021

Journal of Clinical Pathways

NCCN Updates Clinical Practice Guideline for Gastric Cancer

03/10/2021

Janelle Bradley

The National Comprehensive Cancer Network released an update to its clinical practice guideline for gastric cancer.

The National Comprehensive...

03/10/2021

Journal of Clinical Pathways

News

First-Line Biosimilar-Based Triplet Effective in HER2-Positive Gastric Cancer

07/08/2020

A first-line triplet regimen consisting of pembrolizumab, biosimilar trastuzumab (Herzuma), and chemotherapy is effective in patients with HER2-positive advanced gastric cancer, according to the results of a phase...

A...

07/08/2020

Journal of Clinical Pathways

News

Deep Learning Model Accurately Predicts Risk of OS in Gastric Cancer

06/22/2020

A novel deep learning model may accurately predict the risk for overall survival (OS) based on computed tomography (CT) images. Improved risk prediction of OS in gastric cancer is needed in order to guide...

A...

06/22/2020

Journal of Clinical Pathways

Research in Review

Post-Surgery Complications for Gastric Cancer Significantly Raise Hospital Costs

06/29/2017

JCP Editors

Major complications following total gastrectomy for gastric adenocarcinoma can triple the amount of standard hospital costs, according to research published in JAMA Surgery (published online June 28, 2017;...

Major...

06/29/2017

Journal of Clinical Pathways

Research in Review

Higher Dose Does Not Improve Efficacy of Gastric Cancer Treatment

06/20/2017

JCP Editors

A higher dose treatment for a type of metastatic gastric adenocarcinoma showed equivalent efficacy and safety, according to research published in the Journal of Clinical Oncology (published online June 2017;...

A...

06/20/2017

Journal of Clinical Pathways

Clinical Pathways for Advance Stage Gastric Cancer: Standardizing Practice to Decrease Variability and Improve Outcomes

06/13/2017

EXECUTIVE SUMMARY Gastric cancer is the fifth most diagnosed cancer worldwide and the third leading cause of cancer deaths. In the United States and other countries with low rates of gastric cancer, the population...

...

06/13/2017

Journal of Clinical Pathways

Research in Review

Type of Low-Grade Tumor Commonly Over-Diagnosed, Study Suggests

06/12/2017

JCP Editors

A recent study showed that over 65% of cases of a certain tumor type were over-diagnosed or inaccurately risk-stratified, published in PLOS One (June 7, 2017;12[6]:e0179216). ----- Related Content Modified...

A...

06/12/2017

Journal of Clinical Pathways

Research in Review

MicroRNA a Novel Biomarker for Gastric Cancer

10/12/2016

JCP Editors

Serum microRNA-206 (miRNA) may serve as not only a novel diagnostic biomarker for gastric cancer but also as an indicator of prognosis and cancer recurrence, according to a study published in Cellular Physiology and...

Serum...

10/12/2016

Journal of Clinical Pathways

Research in Review

Among European Nations, Greater Clinical Standardization Needed for Patients With Cancer

03/08/2016

JCP Editors

A questionnaire issued to experts in 14 European countries that use oncology clinical pathways has identified the need for greater standardization of clinical practices for patients with esophageal and gastric...

...

03/08/2016

Journal of Clinical Pathways